A new pain medication, part of Indianapolis-based Eli Lilly’s non-opioid pain management platform, took another step forward.
The drug is called galcanezumab. It’s one of three being crafted by Eli Lilly to treat chronic and serious pain. The medicine has shown promising results in a series of trials says Dr. Robert Conley, Lilly global development leader for migraine.
“Around 60 percent of our patients lost more than half of their headache days and some patients even got to 100 percent loss of headache,” says Conley